CellCentric is a drug discovery company focused on epigenetics, a major new area for novel small molecule therapeutics. The company is pursuing novel treatments for prostate, breast and amongst other cancers. Histone modifying enzymes are targeted, including a methyltransferase, demethylase and a ubiquitin modifying protein. CellCentric’s competitive advantage comes from its relationships with over 30 leading research centres worldwide from which it gains privileged information, from target discovery insights through to clinical relevance and patient data. Validation of the company’s approach has come from business development deals achieved with several major pharmaceutical companies.
CellCentric is based in Cambridge UK, a world leading centre for epigenetics in terms of basic research, innovation and translation. The company is headed by an experienced management team with a track record of building businesses and delivering scientific and financial success.